Minggui Pan, MD
Medical Oncology · Stanford, CANPI 1568549418
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Aadi Bioscience, Inc. at 46.8% of the total. Reporting peaked in 2023 at $6,314 and has fallen 98.0% since, to $125 in 2025.
Across 11 payments — averaging $601.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$3K
- Boehringer Ingelheim$3K
- Exelixis Inc.$325
- Rigel Pharmaceuticals, Inc.$141
- Astellas Pharma US Inc$118
- Genentech USA, Inc.$36
Across 3 payments — averaging $13,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
What the payments were for
- Consulting fees$2,90044%
- Speaking & faculty fees$2,76042%
- Food & beverage$96014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 4 | $3,099 |
| Boehringer Ingelheim | 1 | $2,900 |
| Exelixis Inc. | 3 | $325 |
| Rigel Pharmaceuticals, Inc. | 1 | $141 |
| Astellas Pharma US Inc | 1 | $118 |
| Genentech USA, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,620 in reported general payments places this provider in the 55th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZarxioFilgrastim-Sndz | 16 | $55,286 |
| EliquisApixaban | 20 | $11,002 |
| Imatinib Mesylate | 12 | $554 |
| Klor-ConPotassium Chloride | 12 | $533 |
| Oxycodone Hcl | 12 | $175 |
| Ondansetron Hcl | 13 | $88 |
| Prednisone | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.